問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberD933AC00001
Active

2019-04-02 - 2025-10-31

Phase III

Terminated9

ICD-10K83.5

Biliary cyst

ICD-10K83.8

Other specified diseases of biliary tract

ICD-10K87

Disorders of gallbladder, biliary tract and pancreas in diseases classified elsewhere

ICD-9576.8

Other specified disorders of biliary tract

  • Trial Applicant

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator Sheng-Shun Yang Digestive System Department

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Ming-Huang Chen Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Jen-Shi Chen Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 饒坤銘 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Shang-Hung Chen Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator

Co-Principal Investigator

  • 蔡郁棻 Division of Hematology & Oncology

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 官鋒澤 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Chih-Hung Hsu Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Tai-Jan Chiu Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    30 participants

  • Global

    474 participants